Tijaabo caafimaad oo ku saabsan daawaynta unug ee CAR-T ee bukaanada qaba BCMA/TACI-soo laabashada togan iyo/ama dhawrka myeloma refractory

Tijaabooyin caafimaad oo kansarka ah
Tani waa cudud keliya, sumad furan, daraasad hal xarun ah. Daraasaddan waxaa lagu tilmaamay soo noqnoqoshada ama dib u laabashada BCMA/TACI ee soo noqoshada togan iyo/ama laabatooyinka badan ee myeloma. Xulashada heerarka qiyaasta iyo tirada maadooyinka waxay ku saleysan yihiin tijaabooyinka bukaan-socodka ee alaabada ajnabiga ah ee la midka ah. 36 bukaan ayaa la diiwaan gelin doonaa. Ujeedada koowaad waa in la sahamiyo badbaadada, tixgelinta ugu weyni waa badbaadada la xiriirta qiyaasta.

La qaybso Post this

Soo koobid Kooban:

Daraasad ku saabsan APRIL Daaweynta unugyada CAR-T loogu talagalay bukaanada qaba BCMA/TACI ee soo laabashada togan iyo/ama dhawrka myeloma refractory

Faahfaahin faahfaahsan:

This is a single arm, open-label, single-center study. This study is indicated for relapsed or refractory BCMA/TACI positive relapsed and/or refractory multiple myeloma. The selection of dose levels and the number of subjects are based on tijaabada caafimaadka of similar foreign products. 36 patients will be enrolled. The primary objective is to explore safety; the main consideration is dose-related safety.

Shuruudaha

Shuruudaha ka mid noqoshada:

  1. Histologically confirmed diagnosis of BCMA/TACI+ Meelo badan (MM):
    1. Bukaanka qaba MM ee soo noqday ka dib daawaynta BCMA CAR-T; Ama MM oo leh tibaax BCMA/TACI togan;
    2. Dib u soo noqday ka dib wareejinta unugyada tarma ee hematopoietic;
    3. Kiisaska leh cudur hadhaaga ah oo soo noqnoqda;
    4. Dhaawac ka baxsan, oo ay adag tahay in lagu ciribtiro kiimoterabiga ama shucaaca.
  2. Lab ama naag da'doodu u dhaxayso 18-75;
  3. Wadarta bilirubin ≤ 51 umol/L, ALT iyo AST 3 jeer xadka sare ee caadiga ah, creatinine ≤ 176.8 umol/L;
  4. Echocardiogram wuxuu muujinayaa jajabka ka saarista ventricular ventricle (LVEF) ≥50%;
  5. Ma jiro caabuq firfircoon oo ku dhaca sambabada, qoyaanka oksijiinta dhiiga ee hawada gudaha waa ≥ 92%;
  6. Qiyaasta wakhtiga badbaadada ≥ 3 bilood;
  7. Heerka waxqabadka ECOG 0 ilaa 2;
  8. Bukaanka ama mas'uuliyiinta sharciga ah ayaa iskaa wax u qabso ah si ay uga qaybqaataan daraasadda oo ay saxeexaan oggolaanshaha la wargeliyey.

Shuruudaha Ka-saarista:

Mawduucyada leh mid ka mid ah shuruudaha soo socda ee ka saarida uma ay banaanayn tijaabadan:

  1. Taariikhda dhaawacyada craniocerebral, khalkhalka miyir-qabka, suuxdin, ischemia cerebrovascular, iyo cerebrovascular, cudurrada dhiigbaxa;
  2. Electrocardiogram wuxuu muujinayaa dhexda QT oo dheer, cudurada wadnaha oo daran sida wadna xanuun daran waagii hore;
  3. Haweenka uurka leh (ama nuujinaya);
  4. Bukaanka qaba caabuqyo firfircoon oo daran (marka laga reebo caabuqa kaadi mareenka fudud iyo pharyngitis bakteeriyada);
  5. Caabuqa firfircoon ee fayraska cagaarshow B ama fayraska cagaarshow C;
  6. Daawaynta isku dhafka ah ee steroids habdhiska 2 toddobaad gudahood ka hor baaritaanka, marka laga reebo bukaanada dhawaan ama hadda qaata steroids haled;
  7. Markii hore lagu daweeyay wax kasta oo unug CAR-T ah ama daawaynta unugyada kale ee hidde ahaan wax laga beddelay;
  8. Creatinine> 2.5 mg/dl, ama ALT/AST> 3 jeer oo xadiga caadiga ah, ama bilirubin> 2.0 mg/dl;
  9. Cudurada kale ee aan la xakamayn ee aan ku haboonayn tijaabadan;
  10. Bukaanka qaba caabuqa HIV;
  11. Xaalad kasta oo uu baaruhu aaminsan yahay waxay kordhin karaan halista bukaanka ama faragelinayaan natiijada daraasadda

Ku soo Dhawo Wargeyskayaga

Hel wax cusub oo waligaa ha ka maqnaan blog ka Cancerfax

Inbadan Oo La Baadho

Daawaynta Unug ee CAR T ee Ku Salaysan Aadanaha: Horumarrada iyo Caqabadaha
Daaweynta T-Cell-ka Baabuurka

Daawaynta Unug ee CAR T ee Ku Salaysan Aadanaha: Horumarrada iyo Caqabadaha

Daawaynta Unugyada CAR-ku-salaysan ee bini-aadmigu waxa ay wax ka beddeshaa daawaynta kansarka iyada oo hidde ahaan wax ka beddeleysa unugyada difaaca bukaanka si ay u beegsato oo ay u burburiso unugyada kansarka. Ka faa'iidaysiga awoodda habka difaaca jidhka, daawayntani waxay bixiyaan daweyn awood leh oo shakhsi ahaaneed oo leh suurtagalnimada cafis waara ee noocyada kala duwan ee kansarka.

Fahamka Cytokine Release Syndrome: Sababaha, Calaamadaha, iyo Daaweynta
Daaweynta T-Cell-ka Baabuurka

Fahamka Cytokine Release Syndrome: Sababaha, Calaamadaha, iyo Daaweynta

Cytokine Release Syndrome (CRS) waa falcelin habdhiska difaaca oo inta badan ka dhasha daawaynta qaarkood sida immunotherapy ama daawaynta unugga CAR-T. Waxay ku lug leedahay sii-deynta xad-dhaafka ah ee cytokines, taasoo keenta calaamado u dhexeeya qandho iyo daal ilaa dhibaatooyin nafta halis gelin kara sida dhaawaca xubnaha. Maareyntu waxay u baahan tahay kormeer taxadar leh iyo xeelado faragelineed.

Ma u baahan tahay caawimaad? Kooxdayadu waxay diyaar u yihiin inay ku caawiyaan.

Waxaan u rajeynaynaa caafimaad deg-deg ah mid aad jeceshahay iyo mid kuu dhow.

Bilow sheekada
Waxaan nahay Online! Nala hadal!
Sawir koodka
Hello,

Ku soo dhawoow CancerFax!

CancerFax waa madal horudhac ah oo u heellan in lagu xidho shakhsiyaadka wajahaya kansarka heerka sare ee daawaynta unugyada sida CAR T-Cell therapy, daawaynta TIL, iyo tijaabooyinka caafimaad ee adduunka oo dhan.

Nala soo socodsii waxaan kuu qaban karno.

1) Daaweynta kansarka ee dibadda?
2) CAR T-Cell therapy
3) Tallaalka kansarka
4) La-talinta fiidiyowga ee khadka tooska ah
5) daawaynta Proton